China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SHE: 000999) and BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) announced that Phase III clinical study results for BGM0504 injection, a GLP‑1/GIP dual receptor agonist, were presented as an oral presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026). The trial, conducted in 652 overweight or obese Chinese participants, met its primary endpoint and all key secondary endpoints, demonstrating mean body weight reductions of up to 19.2% at 52 weeks with good overall safety and tolerability.
Clinical Evidence – Phase III Weight Loss Study
The BGM0504 Phase III weight loss study was a multicenter, randomized, double‑blind, placebo‑controlled clinical trial that enrolled 652 overweight or obese participants, who received BGM0504 injection at doses of 5 mg, 10 mg, or 15 mg, or placebo, for 52 weeks.
| Endpoint | BGM0504 5 mg | BGM0504 10 mg | BGM0504 15 mg | Placebo |
|---|---|---|---|---|
| Mean Body Weight Reduction from Baseline (Week 52) | 14.3% | 17.3% | 19.2% | 3.1% |
| Absolute Difference vs. Placebo | −11.2 ppt | −14.2 ppt | −16.1 ppt | — |
Key Secondary Endpoints – Additional Metabolic Benefits:
- Blood Pressure: Improvements observed across all BGM0504 dose groups
- Glycated Hemoglobin (HbA1c): Favorable reductions vs. placebo
- Fasting Blood Glucose: Improvements across treatment arms
- Fasting Insulin: Reductions observed, indicating improved insulin sensitivity
- Insulin Resistance Index (HOMA‑IR): Improvements across all active dose groups
Safety: BGM0504 demonstrated good overall safety and tolerability across all dose levels through 52 weeks of treatment.
Drug Profile & Mechanism of Action
- Molecule: BGM0504, a dual GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptor agonist.
- Developer: Independently developed by BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166).
- Mechanism: Dual incretin receptor agonism leverages complementary pathways — GLP‑1 promotes satiety, slows gastric emptying, and enhances glucose‑dependent insulin secretion; GIP amplifies insulinotropic effects and may improve tolerability — producing synergistic effects on weight loss and metabolic parameters.
- Formulation: Subcutaneous injection.
- Competitive Positioning: BGM0504 enters the same pharmacological class as tirzepatide (Mounjaro®/Zepbound®, Eli Lilly), the first dual GLP‑1/GIP agonist approved globally, positioning BGM0504 as a domestically developed alternative for the Chinese market.
Partnership & Commercialization Framework
| Item | Detail |
|---|---|
| Partners | CR Sanjiu (SHE: 000999) and BrightGene (SHA: 688166) |
| Agreement Date | 1 August 2025 |
| CR Sanjiu Rights | Exclusive co‑development right (sublicensable) and exclusive commercialization right (sublicensable) in mainland China (excluding Hong Kong, Macau, and Taiwan) |
| BrightGene Rights | Retains rights outside mainland China; co‑development partner |
| Territory | Mainland China |
Market Impact & Outlook
- China Obesity Epidemic: China has the world’s largest obese population, with over ~500 million adults classified as overweight or obese. The addressable market for pharmacological weight management is expanding rapidly as awareness, access, and reimbursement pathways evolve.
- 19.2% Weight Loss – Clinically Meaningful: The 19.2% mean body weight reduction at the 15 mg dose places BGM0504 in a competitive efficacy range comparable to leading global incretin therapies, representing a potentially best‑in‑class profile within the Chinese GLP‑1/GIP dual agonist pipeline.
- Dose‑Response Relationship: The clear dose‑response gradient (14.3% → 17.3% → 19.2%) provides clinical flexibility for physicians to balance efficacy and tolerability across patient subpopulations.
- Metabolic Pleiotropy: Beyond weight loss, the demonstrated improvements in blood pressure, HbA1c, fasting glucose, insulin, and HOMA‑IR position BGM0504 as a comprehensive metabolic intervention — relevant for the large comorbid population of obesity with type 2 diabetes or metabolic syndrome.
- EASD Oral Presentation: Selection for an oral presentation at EASD — one of the world’s most prestigious diabetes and metabolism conferences — signals that the data were judged to be of high scientific significance by peer reviewers, enhancing the program’s credibility with the global medical community.
- CR Sanjiu Commercial Muscle: China Resources Sanjiu, as one of China’s largest OTC and prescription pharmaceutical companies, brings extensive commercial infrastructure spanning hospital, retail pharmacy, and digital health channels — a significant advantage for scaling BGM0504 in the competitive Chinese obesity market.
- Competitive Landscape: BGM0504 competes in an increasingly crowded Chinese GLP‑1 space that includes semaglutide (Novo Nordisk), tirzepatide (Eli Lilly), and multiple domestic GLP‑1 and GLP‑1/GIP candidates in late‑stage development. Differentiation will depend on the totality of efficacy, safety, dosing convenience, pricing, and potential for additional indications (e.g., type 2 diabetes, NASH/MASH).
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development plans, regulatory timelines, and commercial expectations for BGM0504. Actual results may differ materially due to risks including regulatory review outcomes, additional clinical trial requirements, competitive dynamics in the Chinese obesity and diabetes markets, pricing and reimbursement negotiations, manufacturing scale‑up, and the inherent uncertainties of pharmaceutical development and commercialization. Investors are advised to exercise caution.-Fineline Info & Tech
